ArticleSurgical case reports2026
Successful Conversion Surgery after S-1 plus oxaliplatin Plus Zolbetuximab for Initially Unresectable Gastric Cancer with Pancreatic Invasion: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionZolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), has recently demonstrated significant survival benefits when combined with chemotherapy for advanced gastric cancer. However, evidence regarding conversion surgery following SOX plus zolbetuximab therapy remains extremely limited. CASE PRESENTATION: A 59-year-old woman presented with epigastric discomfort. Endoscopy revealed a depressed lesion in the lower gastric body, and biopsy confirmed signet-ring cell carcinoma. Imaging and diagnostic laparoscopy indicated Type 4 gastric cancer with pancreatic invasion (cT4b, cN0, cP0, cCY0, cM0, cStage IVA). The tumor was HER2-negative, mismatch-repair proficient, PD-L1 combined positive score <1, and strongly positive for CLDN18.2. The patient received 13 courses of SOX plus zolbetuximab, resulting in radiological downstaging (ycT4a, ycN0, ycM0, ycStage IIB). It was determined that an R0 resection was feasible, and total gastrectomy with D2 lymphadenectomy and Roux-en-Y reconstruction was performed. Pathology revealed a minimal residual tumor (5 × 2 mm) with ypT2, ypN0, ypStage IB and a histological response of Grade 2b. R0 resection was achieved. The patient remains recurrence-free 7 months postoperatively.
conclusionsTo our knowledge, this is the first published case describing successful conversion surgery following SOX plus zolbetuximab therapy. This case suggests that CLDN18.2-targeted therapy may facilitate curative resection in selected patients with initially unresectable gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.